A former employee of Swiss pharmaceutical giant Novartis AG's Japanese unit has been found not guilty of exaggerating advertising claims for the blood pressure-lowering drug Diovan. Besides clearing 66-year-old Nobuo Shirahashi on Thursday of violating a pharmaceutical affairs law that bans fraudulent and exaggerated advertising, ...
The health ministry will censure a Japanese unit of Swiss pharmaceutical giant Novartis AG for failing to report serious side effects from some of its drugs within a certain period of time, sources close to the matter said Wednesday. The Ministry of Health, Labor and ...
Gene therapy for deafness is moving closer to reality, with new research on Wednesday showing the technique for fixing faulty DNA can improve responses in mice with genetic hearing loss. Separately, a clinical trial backed by Novartis is under way to help a different group ...
Tokyo prosecutors charged Novartis Pharma K.K. and a former employee Tuesday with causing a medical research team to release data manipulated in favor of the firm's drug for treating high blood pressure in 2011. The prosecutors also issued a fresh arrest warrant for the former ...
A former employee of Novartis Pharma K.K. has been arrested for allegedly manipulating clinical study data for one of the company’s drugs.
The manipulation of clinical research data used to develop the blood pressure drug Diovan sold by Novartis Pharma K.K. has prompted a special squad of Tokyo prosecutors to search the Japanese unit of the Swiss drugmaker as well as the universities that conducted the ...
Tokyo prosecutors raided Novartis Pharma K.K. on Wednesday over its alleged use of exaggerated advertising for a blood pressure-lowering drug, following a criminal complaint filed by the health ministry last month. The ministry claimed that the ads for Diovan cited clinical study reports by two ...
A health ministry panel is questioning Novartis Pharma K.K.'s use of clinical research data in promoting the sale of Diovan, its drug to lower blood pressure, saying it "could constitute misleading advertisement" after revelations that some of the data were manipulated. The Japanese unit of ...
The health ministry has instructed Novartis Pharma K.K. to state in an attached note for its Diovan blood pressure-lowering drug that the medicine may cause serious skin disorders. Diovan, whose generic name is valsartan, has been cited in a recent suspected case of clinical data ...
A Kyoto university's announcement that research on blood-pressure drug Diovan was manipulated raises concerns about the drugmaker's objectivity.
A lack of balance exists between the health needs of really poor people in the world and the market for helping the rich and super-rich lead a fashionable lifestyle.
